[Therapy of endometriosis with dienogest].

G Köhler, Günter Köhler, G Göretzlehner, G Görétzlehner, I Amon
Zentralblatt fur Gynakologie · 1987 · vol. 109(12) , pp. 795–801 · PMID:3630463 · W2416048052
article OA: closed CC0 ⤵ 12 in-corpus citations
View on OpenAlex View on PubMed
⚙ AI-generated summary by claude@2026-06, 2026-06-07 ⓘ

Dienogest, an orally active progestin, treated 57 women with endometriosis for 6 months, showing lesion disappearance in 66.7%, improvement in 80.4%, and symptomatic relief in 84%, with spotting and decreased libido as main side effects.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Dienogest (17 alpha-cyanomethyl-17 beta-hydroxy-estra-4,9-dien-3-one, VEB Jenapharm, Jena, GDR), an orally active 19-nortestosterone derivative, was used firstly in the treatment of endometriosis. 57 patients (age 17-45 years) have been entered into the study. The diagnosis was confirmed by laparoscopy or laparotomy in 56 cases and in one case clinically. All patients have been treated with 2 mg dienogest per day in a progestin only regimen over a period of 6 month. The day after completing the course of dienogest therapy 51 patients underwent laparoscopy for control. On this basis endometriotic lesions had completely disappeared in 66.7%; in 80.4% a marked improvement was noted, but no effect was visible in 19.6% of the implants. Eighty-four per cent of the women reported symptomatic improvement. The efficacy of dienogest was correlated negative with the age of the treated women. The major side effects were spottings and decrease of libido. Blood pressure as well as mean body weight remained unaltered. No patient discontinued dienogest therapy due to side effects.

My notes (saved in your browser only)

Condition tags

endometriosis

MeSH descriptors

Endometriosis Genital Neoplasms, Female Nandrolone Progesterone Congeners Adolescent Adult Endometriosis Female Follow-Up Studies Genital Neoplasms, Female Humans Middle Aged Nandrolone Nandrolone Nandrolone Progesterone Congeners Progesterone Congeners

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

Cited by (12)

Source provenance

europepmc
last seen: 2026-06-13T06:22:48.782012+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-13T22:09:30.565292+00:00
License: CC0 · commercial use OK